Advertisement

Comparison between specific and nonspecific assay in the evaluation of the anticoagulant effect of the Direct Oral Anticoagulants: Our experience in a cardiovascular hospital

Published:October 12, 2018DOI:https://doi.org/10.1016/j.ejim.2018.10.005
      The new generation of antithrombotic agents, known as Direct Oral Anticoagulants (DOACs), act on a single factor within the coagulation cascade. Although the monitoring of therapy is not necessary for DOACs, measuring the anticoagulant effect is useful in many clinical situations, especially pre-operative evaluation [
      • Tripodi A.
      To measure or not to measure direct oral anticoagulants before surgery or invasive procedures.
      ]. Specific tests, which quantify the drug indirectly, and nonspecific tests, which are altered by DOACs, are used to evaluate the anticoagulant effect of DOACs. The aim of this study is to assess the responsiveness of the specific and non-specific assays used at IRCCS Policlinico San Donato to low DOAC concentrations and to compare the responsiveness between calibrators and patients with nonspecific assays.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tripodi A.
        To measure or not to measure direct oral anticoagulants before surgery or invasive procedures.
        J Thromb Haemost. 2016; 14: 1325-1327
        • Douxfils J.
        • Mullier F.
        • Robert S.
        • et al.
        Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
        Thromb Haemost. 2012; 107: 985-997
        • Testa S.
        • Legnani C.
        • Tripodi A.
        • et al.
        Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: Results from a multicenter/multiplatform study.
        J Thromb Haemost. 2016; 14: 2194-2201
        • Baglin T.
        • Keeling D.
        • Kitchen S.
        Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology.
        Br J Haematol. 2012; 159: 427-429
        • Baglin T.
        • Hillarp A.
        • Tripodi A.
        • et al.
        Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and Standardisation Committee of the International Society on thrombosis and haemostasis.
        J Thromb Haemost. 2013; 11: 756-760
        • Lim M.S.
        • Chapman K.
        • Swanepoel P.
        • et al.
        Sensitivity of routine coagulation assays to direct oral anticoagulants: Patient samples versus commercial drug-specific calibrators.
        Pathology. 2016; 48: 712-719
        • Gosselin R.C.
        • Adcock D.
        • Hawes E.M.
        • et al.
        Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
        Thromb Haemost. 2015; 113: 77-84
        • Hawes E.M.
        • Deal A.M.
        • Funk-Adcock D.
        • et al.
        Performance of coagulation tests in patients on therapeutic doses of dabigatran: A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
        J Thromb Haemost. 2013; 11: 1493-1502
        • Tripodi A.
        • Padovan L.
        • Testa S.
        • et al.
        How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study.
        Clin Chem Lab Med. 2015; 53: 265-273